Global Congestive Heart Failure Therapies Market

Growth in the pharmaceutical management market of congestive heart failure (CHF) is being driven by an increased incidence of CHF, the application of innovative technologies in search of targeted therapies, and physicians prescribing multi-drug regimens in response to the failure of traditional drugs to treat CHF.

According to a new report by Kalorama Information (New York, NY, USA), the global market for drugs to treat CHF will continue to be dominated by major pharmaceutical companies, which supply product lines with broad cardiovascular applications. There are, however, many smaller companies focusing primarily on CHF and biotech, and their numbers are growing with the realization that this disease presents a major economic opportunity for which there is currently no adequate answer. CHF is a complex disorder for which prevention is more effective than treatment, and as part of the larger cardiovascular markets, it is mostly treated with drugs used to treat many other cardiovascular disorders. The lack of targeted treatments means drugs will continue to be applied liberally for prevention and sales will grow disproportionately to the CHF patient population. The Kalorama report covers current pharmaceutical treatments in the key categories used to treat CHF, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs); Beta-blockers; diuretics; inotropes; vasodilators; and aldosterone inhibitors. However, the future of CHF treatment may lie elsewhere.

"The future of CHF drug treatments lies in newer technologies such as biotechnology and genomics,” said Kalorama analyst Kenneth Krul, Ph.D., MBA. "The identification of fetal genes associated with CHF, new treatments that address the endothelium and cell therapy to regenerate damaged heart muscle tissue present some promising areas.”

Kalorama Information estimated that the market for congestive heart failure (CHF) drug treatments was $18 billion in 2007, and it is expected to reach $30 billion by 2017.


Related Links:
Kalorama Information